1. Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(42):15539–48.
2. European Medicines Agency. Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infections liver disease (PBC, PSC, NASH); 2018.
https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-chronic-non-infectious-liver_en.pdf
. Accessed 26 Nov 2018.
3. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and causes of NAFLD and NASH; 2016.
https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/symptoms-causes
. Accessed 12 Oct 2018.
4. Corte CD, Ferrari F, Villani A, Nobili V. Epidemiology and natural history of NAFLD. J Med Biochem. 2015;34(1):13–7.
5. Wegermann K, Diehl AM, Moylan CA. Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis. Clin Liver Dis. 2018;11(4):87–91.